Ginsenosides in the management of depression: a comprehensive pharmacological review

Depression is a prevalent and debilitating psychiatric disorder that is frequently accompanied by chronic conditions such as cancer, cardiovascular diseases, and neurological disorders. Despite the availability of various pharmacological treatments, their limited efficacy and frequent side effects have prompted growing interest in natural compounds with antidepressant potential. Panax ginseng, a traditional herbal medicine widely used in East Asia, contains diverse bioactive components, among which ginsenosides are recognized as the principal active constituents. Ginsenosides, primarily classified into dammarane-type and oleanane-type saponins, exhibit antidepressant-like effects through multiple interconnected biological mechanisms. These include modulation of monoaminergic neurotransmission, regulation of the hypothalamic-pituitary-adrenal (HPA) axis, promotion of neurogenesis and synaptic plasticity, mitigation of neuroinflammation and oxidative stress, and restoration of gut microbiota homeostasis. Recent investigations also highlight enhanced bioavailability and therapeutic promises of rare ginsenosides, such as ginsenosides Rg3, Rk1 and Rg5, with fewer sugar moieties, suggesting unique advantages for clinical application. This review consolidates current evidence on the pharmacological activities, molecular targets, and therapeutic potential of ginsenosides in the management of depression. By integrating findings from experimental and limited clinical studies, it aims to provide a rational scientific framework to inform future investigation and development of ginsenoside-based strategies for depression, while emphasizing the need for further rigorous clinical validation.